

Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk.

Laufs U, et al. Clin Res Cardiol. 2016; 105(9):783-90.

- Limited data is available on current use and effectiveness of atorvastatin outside of randomised trials.
- A total of 2625 high-risk patients on atorvastatin were included into a cross-sectional study by 539 office-based physicians between June and December 2014 [47.0 % of the patients had documented coronary heart disease (CHD), 25.1 % type 2 diabetes mellitus (DM), and 27.9 % CHD plus concomitant DM].
- According to physicians' subjective assessment, 62.7 % of patients had reached their individual LDL-C target. Higher doses of atorvastatin (40 mg/day, 80 mg/day) had not been frequently needed.

Atorvastatin treatment facilitates LDL-C target attainment in patients with high cardiovascular risk.